Mobile navigation menu modal
As cell and gene therapies (CGTs) continue to enter the market, treatment centers have become the primary gatekeepers...
Free drug removes price barriers, but Otarmeni shows why specialty therapy access still depends on PSPs, payers, and logistics.
How CGT manufacturers can reduce financial risk and reimbursement burden for treatment centers adopting commercial therapies.
How CGT manufacturers can reduce treatment center burden through better workflows, training, logistics, and system integration.
Overcome CGT capacity challenges with strategies for forecasting, staffing, and treatment center partnerships.
PURE Engagement: OBBBA Medicaid shifts may raise coverage churn, provider risk, and affordability pressures—forcing pharma to rethink market access.
How biopharma can transition patient support vendors while minimizing disruption and improving the patient and provider experience.
Discover how PURE Engagement transforms patient support programs to improve adherence, HCP engagement, and long-term health outcomes.
Nuvera expands its data-driven solutions and strengthens its leadership team to enhance patient and HCP treatment experiences.
We are pleased to announce that Derek Cothran has assumed the role of Managing Principal at Nuvera Life Science Consulting.
Explore the vital role of caregivers and why greater engagement is key to enhancing patient support and healthcare outcomes.
Nuvera’s PURE Report honors 2023’s best-in-class pharma patient support & access programs in oncology and neurology. See the top picks.
We create effective treatment experience strategies through experience and market insights.
